UM-UC-14Homo sapiens (Human)Cancer cell line
Also known as: University of Michigan-Urothelial Carcinoma-14, UMUC14, UM-UC14, UMUC-14
🤖 AI SummaryBased on 5 publications
Quick Overview
Human bladder cancer cell line with known genetic alterations and applications in cancer research.
Detailed Summary
UM-UC-14 is a human bladder cancer cell line derived from transitional cell carcinoma. It is utilized in research for studying genetic mutations, tumor progression, and therapeutic responses. The cell line has been characterized for its TP53 mutations and p53 protein expression, which are critical in bladder cancer studies. UM-UC-14 is also used in investigations related to cell line authentication and cross-contamination, as highlighted in studies on short tandem repeat (STR) profiling. Additionally, it has been involved in research on TERT promoter mutations, which are significant in bladder cancer diagnostics and prognosis. The cell line's utility extends to in vitro and in vivo models for understanding bladder cancer biology and developing targeted therapies.
Research Applications
Genetic mutation analysisTumor progression studiesTherapeutic response evaluationCell line authenticationTERT promoter mutation research
Key Characteristics
TP53 mutationsp53 protein expressionSTR profilingTERT promoter mutations
Generated on 6/19/2025
Basic Information
| Database ID | CVCL_2747 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Kidney, renal pelvis[UBERON:UBERON_0001224] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Renal pelvis carcinoma |
|---|---|
| Lineage | Bladder/Urinary Tract |
| Subtype | Urethral Urothelial Carcinoma |
| OncoTree Code | UCU |
DepMap Information
| Source Type | Sigma-Aldrich |
|---|---|
| Source ID | ACH-001408_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg280Thr (c.839G>C) | Heterozygous | - | Unknown, PubMed=12872257 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
10,11
D13S317
12
D16S539
12,13
D18S51
12,15
D21S11
30.2,31.2
D3S1358
14,17
D5S818
11,12
D7S820
9,12
D8S1179
13,15
FGA
24,25
Penta D
9,14
Penta E
12,18
TH01
9.3
TPOX
8,11
vWA
15,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Bladder Cancer 4:169-183(2018).
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:403.1-403.16(2015).
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Hurst C.D., Platt F.M., Knowles M.A.
Eur. Urol. 65:367-369(2014).
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Eur. Urol. 65:360-366(2014).
The use of short tandem repeat profiling to characterize human bladder cancer cell lines.
Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.
J. Urol. 181:2737-2748(2009).
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
Czerniak B.
J. Natl. Cancer Inst. 100:1401-1411(2008).